Drugs / AWD-12-281
AWD-12-281
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00356642 | Jun → Dec 2005 | atopic eczema | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00354510 | Mar 2006 → ? | atopic eczema | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AWD-12-281 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3218685 ↗ |
| Known as | GSK-842470 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3218685 ↗ |
| Known as | GW-842470 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3218685 ↗ |
| Known as | GW842470X | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00354510 ↗ |
| Action | Inhibit | “GW842470X is an inhibitor of phosphodiesterase 4 (PDE4).” NCT00356642 ↗ |
| Modality | Small molecule | — CHEMBL3218685 ↗ |
| Route | Topical | “Topical GW842470X” NCT00354510 ↗ |